Women with high perioperative risks or low likelihood of achieving cytoreduction < 1 cm (ideally no visible disease) should receive NACT.
NACT is non-inferior to PCS for progression-free and overall survival and has lower peri- and postoperative morbidity and mortality.
However, primary cytoreductive surgery may offer superior survival in selected patients.